{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T12:07:56Z","timestamp":1783339676412,"version":"3.54.6"},"reference-count":79,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,5,23]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immunotherapies targeting programmed cell death-1 (PD-1) and its ligands have improved clinical outcomes for advanced melanoma. However, many tumors exhibit primary resistance or acquire secondary resistance after an initial positive response. The mechanisms of resistance are not well understood, and no validated predictive biomarkers are available. This exploratory study aimed to characterize baseline differences and molecular changes arising during treatment in acral and mucosal melanomas that exhibited primary or secondary resistance to anti-PD-1 monotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was an observational retrospective study of 124 patients who had been treated for metastatic acral or mucosal melanoma with anti-PD-1 monotherapy. Tumor samples were collected at baseline (all patients) and post-treatment (resistant tumors only) and were assayed by immunohistochemistry, whole-exome sequencing, and RNA sequencing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At baseline, more non-progressor than resistant tumors exhibited expression of PD-L1, immune cell infiltration, and high tumor mutational burden (TMB); baseline PD-L1 expression was also more common in secondary-resistant than in primary-resistant tumors as well as in late versus early secondary-resistant tumors. Non-progressor tumors also had higher median baseline expression of an 18-gene T cell-inflamed gene expression profile (Tcell<jats:sub>inf<\/jats:sub>GEP). Among resistant tumors, the proportion of PD-L1-positive melanomas and the expression of the Tcell<jats:sub>inf<\/jats:sub>GEP mRNA signature increased during treatment, while the expression of mRNA signatures related to WNT and INFA1 signaling decreased. There was evidence for greater changes from baseline in secondary-resistant versus primary-resistant tumors for some markers, including expression of RAS-related and WNT-related mRNA signatures and density of CD11c<jats:sup>+<\/jats:sup> and FOXP3<jats:sup>+<\/jats:sup> T cells. Greater changes in CD11c<jats:sup>+<\/jats:sup> cell density were observed in early compared with late secondary-resistant tumors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our findings suggest that Tcell<jats:sub>inf<\/jats:sub>GEP and PD-L1 expression, TMB, immune cell infiltration, and RAS and WNT signaling warrant further investigation as potential mechanisms and\/or biomarkers of anti-PD-1 therapy resistance in acral and mucosal melanomas. Confirmation of these findings in larger populations is needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-004879","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T12:12:20Z","timestamp":1657109540000},"page":"e004879","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":27,"title":["Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5737-9830","authenticated-orcid":false,"given":"Irene M.","family":"Shui","sequence":"first","affiliation":[{"name":"Merck & Co., Inc, Rahway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao Qiao","family":"Liu","sequence":"additional","affiliation":[{"name":"MSD China, Beijing, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc, Rahway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Tae","family":"Kim","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Samsung Medical Center, Gangnam-gu, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Sun","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc, Rahway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer H.","family":"Yearley","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc, Rahway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasmiah","family":"Choudhury","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc, Rahway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Webber","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc, Rahway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Krepler","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc, Rahway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razvan","family":"Cristescu","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc, Rahway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeeyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Samsung Medical Center, Gangnam-gu, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"2025100313342150000_10.7.e004879.1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-3-319-22539-5_2","article-title":"Melanoma epidemiology and prevention","volume":"167","author":"Berwick","year":"2016","journal-title":"Cancer Treat Res"},{"key":"2025100313342150000_10.7.e004879.2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25516"},{"key":"2025100313342150000_10.7.e004879.3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamadermatol.2016.4512","article-title":"Analysis of trends in US melanoma incidence and mortality","volume":"153","author":"Glazer","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2025100313342150000_10.7.e004879.4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-3-319-22539-5_4","article-title":"Melanoma: clinical presentations","volume":"167","author":"Kibbi","year":"2016","journal-title":"Cancer Treat Res"},{"key":"2025100313342150000_10.7.e004879.5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4068\/cmj.2016.52.3.185","article-title":"Cutaneous melanoma in Asians","volume":"52","author":"Kim","year":"2016","journal-title":"Chonnam Med J"},{"key":"2025100313342150000_10.7.e004879.6","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-019-0607-8","article-title":"Targeted therapy and immunotherapy for melanoma in Japan","volume":"20","author":"Namikawa","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"2025100313342150000_10.7.e004879.7","doi-asserted-by":"publisher","DOI":"10.1038\/nature22071"},{"key":"2025100313342150000_10.7.e004879.8","doi-asserted-by":"crossref","DOI":"10.1186\/gm175","article-title":"Environmental exposures and mutational patterns of cancer genomes","volume":"2","author":"Pfeifer","year":"2010","journal-title":"Genome Med"},{"key":"2025100313342150000_10.7.e004879.9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/978-3-319-22539-5_14","article-title":"Acral Lentiginous melanoma","volume":"167","author":"Goydos","year":"2016","journal-title":"Cancer Treat Res"},{"key":"2025100313342150000_10.7.e004879.10","first-page":"739","article-title":"Primary mucosal melanomas: a comprehensive review","volume":"5","author":"Mihajlovic","year":"2012","journal-title":"Int J Clin Exp Pathol"},{"key":"2025100313342150000_10.7.e004879.11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz005"},{"key":"2025100313342150000_10.7.e004879.12","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-013-3089-0"},{"key":"2025100313342150000_10.7.e004879.13","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0522"},{"key":"2025100313342150000_10.7.e004879.14","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.43"},{"key":"2025100313342150000_10.7.e004879.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305133"},{"key":"2025100313342150000_10.7.e004879.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00083-2"},{"key":"2025100313342150000_10.7.e004879.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"2025100313342150000_10.7.e004879.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60958-2"},{"key":"2025100313342150000_10.7.e004879.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"2025100313342150000_10.7.e004879.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"2025100313342150000_10.7.e004879.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.0105"},{"key":"2025100313342150000_10.7.e004879.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8"},{"key":"2025100313342150000_10.7.e004879.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4059"},{"key":"2025100313342150000_10.7.e004879.24","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0287"},{"key":"2025100313342150000_10.7.e004879.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958"},{"key":"2025100313342150000_10.7.e004879.26","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0828"},{"key":"2025100313342150000_10.7.e004879.27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.3002"},{"key":"2025100313342150000_10.7.e004879.28","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"},{"key":"2025100313342150000_10.7.e004879.29","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-1223"},{"key":"2025100313342150000_10.7.e004879.30","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e3181eacbd8"},{"key":"2025100313342150000_10.7.e004879.31","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2703"},{"key":"2025100313342150000_10.7.e004879.32","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2281"},{"key":"2025100313342150000_10.7.e004879.33","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1172-6"},{"key":"2025100313342150000_10.7.e004879.34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.11.015","article-title":"Conserved interferon-\u03b3 signaling drives clinical response to immune checkpoint blockade therapy in melanoma","volume":"39","author":"Grasso","year":"2021","journal-title":"Cancer Cell"},{"key":"2025100313342150000_10.7.e004879.35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.9258"},{"key":"2025100313342150000_10.7.e004879.36","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41416-018-0207-6","article-title":"Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006","volume":"119","author":"Hamid","year":"2018","journal-title":"Br J Cancer"},{"key":"2025100313342150000_10.7.e004879.37","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/bjd.17434","article-title":"Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients","volume":"180","author":"Maeda","year":"2019","journal-title":"Br J Dermatol"},{"key":"2025100313342150000_10.7.e004879.38","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/1346-8138.14637","article-title":"Use of immune checkpoint inhibitors prolonged overall survival in a Japanese population of advanced malignant melanoma patients: retrospective single institutional study","volume":"45","author":"Nakamura","year":"2018","journal-title":"J Dermatol"},{"key":"2025100313342150000_10.7.e004879.39","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2018.09.025","article-title":"Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: an open-label, single-arm, multicentre phase II study","volume":"105","author":"Namikawa","year":"2018","journal-title":"Eur J Cancer"},{"key":"2025100313342150000_10.7.e004879.40","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30259"},{"key":"2025100313342150000_10.7.e004879.41","doi-asserted-by":"crossref","unstructured":"Cristescu R , Aurora-Garg D , Albright A . Association between tumor mutational burden (TMB) assessed by whole-exome sequencing (WES) and outcomes of pembrolizumab (pembro) monotherapy. paper presented at: annual meeting of the American association for cancer research 2020.","DOI":"10.1158\/1538-7445.AM2020-LB-261"},{"key":"2025100313342150000_10.7.e004879.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025100313342150000_10.7.e004879.43","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100313342150000_10.7.e004879.44","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","article-title":"Programmed Death-Ligand 1 expression and response to the Anti-Programmed death 1 antibody pembrolizumab in melanoma","volume":"34","author":"Daud","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025100313342150000_10.7.e004879.45","unstructured":"BWA-MEM [computer program];114."},{"key":"2025100313342150000_10.7.e004879.46","doi-asserted-by":"publisher","DOI":"10.1101\/gr.107524.110"},{"key":"2025100313342150000_10.7.e004879.47","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2514"},{"key":"2025100313342150000_10.7.e004879.48","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"2025100313342150000_10.7.e004879.49","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0974-4"},{"key":"2025100313342150000_10.7.e004879.50","doi-asserted-by":"publisher","DOI":"10.1186\/s13029-016-0060-z"},{"key":"2025100313342150000_10.7.e004879.51","unstructured":"Aurora-Garg D , Albright A , Qiu P . Large-scale evaluation of concordance of genomic scores in whole exome sequencing and Foundation medicine comprehensive genomic platform across cancer types. J Immunother Cancer 2019;7."},{"key":"2025100313342150000_10.7.e004879.52","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bts294"},{"key":"2025100313342150000_10.7.e004879.53","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190"},{"key":"2025100313342150000_10.7.e004879.54","doi-asserted-by":"crossref","unstructured":"Cristescu R , Nebozhyn M , Zhang C . Pan-tumor analysis of the association of cancer and immune biology-related gene expression signatures with response to pembrolizumab monotherapy. J Immunother Cancer 2019;7.doi:10.1126\/science.aar3593","DOI":"10.1126\/science.aar3593"},{"key":"2025100313342150000_10.7.e004879.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2011.03.007"},{"key":"2025100313342150000_10.7.e004879.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.05.012"},{"key":"2025100313342150000_10.7.e004879.57","doi-asserted-by":"crossref","unstructured":"Cristescu R , Nebozhyn M , Zhang C . Transcriptomic determinants of response to pembrolizumab monotherapy across solid tumor types. Clin Cancer Res 2021.","DOI":"10.1158\/1078-0432.CCR-21-3329"},{"key":"2025100313342150000_10.7.e004879.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001"},{"key":"2025100313342150000_10.7.e004879.59","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040889","article-title":"Wnt\/\u03b2-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma","volume":"13","author":"Chehrazi-Raffle","year":"2021","journal-title":"Cancers"},{"key":"2025100313342150000_10.7.e004879.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.11.016"},{"key":"2025100313342150000_10.7.e004879.61","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11060771","article-title":"A review of the role of Wnt in cancer immunomodulation","volume":"11","author":"Goldsberry","year":"2019","journal-title":"Cancers"},{"key":"2025100313342150000_10.7.e004879.62","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00221-9"},{"key":"2025100313342150000_10.7.e004879.63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1090"},{"key":"2025100313342150000_10.7.e004879.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.02.008"},{"key":"2025100313342150000_10.7.e004879.65","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02854","article-title":"Wnt signaling in tumors: the way to evade drugs and immunity","volume":"10","author":"Martin-Orozco","year":"2019","journal-title":"Front Immunol"},{"key":"2025100313342150000_10.7.e004879.66","doi-asserted-by":"publisher","DOI":"10.1124\/mol.119.117978"},{"key":"2025100313342150000_10.7.e004879.67","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1327"},{"key":"2025100313342150000_10.7.e004879.68","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1942"},{"key":"2025100313342150000_10.7.e004879.69","doi-asserted-by":"publisher","DOI":"10.1172\/jci95351"},{"key":"2025100313342150000_10.7.e004879.70","doi-asserted-by":"publisher","DOI":"10.1038\/nature14404"},{"key":"2025100313342150000_10.7.e004879.71","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.117"},{"key":"2025100313342150000_10.7.e004879.72","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6101(01)00022-3"},{"key":"2025100313342150000_10.7.e004879.73","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.14"},{"key":"2025100313342150000_10.7.e004879.74","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-30417-6","article-title":"Inhibiting the CD8+ T cell infiltration in the tumor microenvironment after radiotherapy is an important mechanism of radioresistance","volume":"8","author":"Chen","year":"2018","journal-title":"Sci Rep"},{"key":"2025100313342150000_10.7.e004879.75","doi-asserted-by":"publisher","DOI":"10.1016\/J.CCELL.2019.01.003"},{"key":"2025100313342150000_10.7.e004879.76","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27782"},{"key":"2025100313342150000_10.7.e004879.77","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2010.05.010"},{"key":"2025100313342150000_10.7.e004879.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2017.01.002"},{"key":"2025100313342150000_10.7.e004879.79","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25693"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-004879","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:34:30Z","timestamp":1759523670000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-004879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":79,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,6]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/jitc-2022-004879"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-004879","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}